Clinical Trials Logo

Advanced Cancer clinical trials

View clinical trials related to Advanced Cancer.

Filter by:

NCT ID: NCT00761644 Completed - Advanced Cancer Clinical Trials

Doxil, Bevacizumab and Temsirolimus Trial

Start date: August 21, 2008
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer that has spread or is unable to be surgically removed. The safety and effectiveness of this combination of drugs will also be studied.

NCT ID: NCT00761618 Active, not recruiting - Advanced Cancer Clinical Trials

Intrapleural Catheter Daily Versus Three Times a Week Drainage

Start date: August 22, 2008
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if draining the IPC every day is better at than draining it 3 times a week.

NCT ID: NCT00741403 Completed - Lymphoma Clinical Trials

A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies

Start date: August 2008
Phase: Phase 1
Study type: Interventional

An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives of this study are: - To determine the safety and MTD of CPI-613 when administered 2x weekly for 3 consecutive weeks. - To determine pharmacokinetics of CPI-613 following intravenous (IV) administration. - To observe the anti-tumor effects of CPI-613, if any occur.

NCT ID: NCT00736372 Completed - Metastatic Cancer Clinical Trials

A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a novel small molecule inhibitor of thioredoxin-1, a small protein over-expressed in many human cancers that is associated with aggressive tumor proliferation, angiogenesis, and drug resistance. This study is being conducted to determine the maximally tolerated dose of PX-12 delivered as a 72-hour infusion over days 1, 2, and 3 of a 21-day cycle in patients with advanced or metastatic cancer.

NCT ID: NCT00729833 Terminated - Clinical trials for Advanced Solid Tumors

Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors

Start date: September 2008
Phase: Phase 1
Study type: Interventional

The study is being conducted to determine the maximum tolerated dose, overall safety and tolerability profile, and pharmacokinetic profile of CP-751,871 and sunitinib when given in combination with advanced solid tumors.

NCT ID: NCT00710736 Completed - Advanced Cancer Clinical Trials

A Study of ARRY-334543 and Capecitabine in Patients With Advanced Cancer

Start date: June 2008
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study during which patients with advanced/metastatic solid tumors will receive investigational study drug ARRY-334543 and capecitabine. Patients will receive increasing doses of study drug in combination with capecitabine in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Patients will be followed to see what side effects the combination causes and what effectiveness the combination has, if any, in treating the cancer. Approximately 30 patients from the US and Canada will be enrolled in this study.

NCT ID: NCT00709176 Completed - Advanced Cancer Clinical Trials

Outcomes of Triaged Family Care in Advanced Cancer

FOCUS-Triage
Start date: June 2005
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the quality of life of patients with advanced cancer and their family caregivers and to evaluate two doses of a family-based program of care versus control.

NCT ID: NCT00708773 Completed - Advanced Cancer Clinical Trials

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

Start date: February 2006
Phase: Phase 1
Study type: Interventional

Describe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan in cancer patients with advanced solid tumors with UGT1A1 6/6 and 6/7 genotypes.

NCT ID: NCT00708591 Completed - Advanced Cancer Clinical Trials

Study of Rapamycin Plus Ketoconazole in Advanced Cancers

Start date: October 2004
Phase: Phase 1
Study type: Interventional

To determine the maximum tolerated dose, observed toxicities, and dose limiting toxicities, and antitumor response of rapamycin plus ketoconazole in patients with advanced cancers.

NCT ID: NCT00707135 Completed - Advanced Cancer Clinical Trials

Rapamycin in Advanced Cancers

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The goal of this study is to determine the rapamycin dose equivalent to the recommended phase II/III dose of temsirolimus and determine the observed toxicities and anti-tumor response of rapamycin in patients with advanced cancers.